연구성과로 돌아가기

2021 연구자 정보 (644 / 1146)

※ 컨트롤 + 클릭으로 열별 다중 정렬 가능합니다.
Excel 다운로드
Author Name 제1저자 여부 ⓘ 교신저자 여부 ⓘ Address ResearcherID ORCID Paper Title WoS Edition 최상위 JCR(%) WoS Category Related Email
Jung, Ki Sun
(Jung, KS) ⓘ 		Pusan Natl Univ, Sch Med, Yangsan Hosp, Dept Internal Med,Div Hematol Oncol, Yangsan, South Korea ⓘ
ⓘ
ⓘ 		[JCR상위 26.0] Open-label, single arm, multicenter phase II study of VIDL induction chemotherapy followed by upfront autologous stem cell transplantation in patients with advanced stage extranodal NK/T-cell lymphoma ⓘ SCIE ⓘ 26.0 HEMATOLOGY;IMMUNOLOGY;ONCOLOGY;TRANSPLANTATION ⓘ drydh1685@hotmail.com;wskimsmc@skku.edu; ⓘ
Jung, Seung-Yeon
(Jung, SY) ⓘ 		St Carollo Hosp, Dept Hematol Oncol, Jeollanam, South Korea ⓘ
ⓘ
ⓘ 		[JCR상위 26.0] Allogeneic transplant can abrogate the risk of relapse in the patients of first remission acute myeloid leukemia with detectable measurable residual disease by next-generation sequencing ⓘ SCIE ⓘ 26.0 HEMATOLOGY;IMMUNOLOGY;ONCOLOGY;TRANSPLANTATION ⓘ zhaolei.zhang@utoronto.ca;hjoonk@chonnam.ac.kr;dr.dennis.kim@uhn.ca; ⓘ
Kim, Dennis Dong Hwan
(Kim, DDH) ⓘ 		교신저자 Univ Toronto, Dept Med Oncol & Hematol, Princess Margaret Canc Ctr, Toronto, ON, Canada ⓘ AAH-8499-2019
Kim, Dennis ⓘ
ⓘ 		[JCR상위 26.0] Allogeneic transplant can abrogate the risk of relapse in the patients of first remission acute myeloid leukemia with detectable measurable residual disease by next-generation sequencing ⓘ SCIE ⓘ 26.0 HEMATOLOGY;IMMUNOLOGY;ONCOLOGY;TRANSPLANTATION ⓘ zhaolei.zhang@utoronto.ca;hjoonk@chonnam.ac.kr;dr.dennis.kim@uhn.ca; ⓘ
Kim, Jin Seok
(Kim, JS) ⓘ 		Yonsei Univ, Coll Med, Dept Internal Med, Seoul, South Korea
Yonsei Univ, Div Hematol, Severance Hosp, Coll Med,Dept Internal Med, Seoul, South Korea
Yonsei Univ, Coll Med, Div Hematol, Dept Internal Med,Severance Hosp, Seoul, South Korea ⓘ 		I-6927-2019
KIM, JIN ⓘ 		0000-0001-8986-8436
KIM, JIN SEOK ⓘ 		[JCR상위 26.0] Open-label, single arm, multicenter phase II study of VIDL induction chemotherapy followed by upfront autologous stem cell transplantation in patients with advanced stage extranodal NK/T-cell lymphoma
[JCR상위 43.0] Clinical characteristics and prognostic factors of acquired haemophilia A in Korea
[JCR상위 81.4] Clinical impact of frailty on treatment outcomes of elderly patients with relapsed and/or refractory multiple myeloma treated with lenalidomide plus dexamethasone ⓘ 		SCIE ⓘ 26.0 HEMATOLOGY;IMMUNOLOGY;ONCOLOGY;TRANSPLANTATION
HEMATOLOGY ⓘ 		drydh1685@hotmail.com;wskimsmc@skku.edu;
hemakim@yuhs.ac;
ckmin@catholic.ac.kr; ⓘ
Kim, Kyoung Ha
(Kim, KH) ⓘ 		Univ Toronto, Dept Med Oncol & Hematol, Princess Margaret Canc Ctr, Toronto, ON, Canada
Soonchunhyang Univ Hosp, Dept Internal Med, Seoul, South Korea
Soonchunhyang Univ, Dept Internal Med, Seoul Hosp, Seoul, South Korea ⓘ
ⓘ
ⓘ 		[JCR상위 26.0] Allogeneic transplant can abrogate the risk of relapse in the patients of first remission acute myeloid leukemia with detectable measurable residual disease by next-generation sequencing
[JCR상위 51.9] Ultra-deep sequencing mutation analysis of the BCR/ABL1 kinase domain in newly diagnosed chronic myeloid leukemia patients ⓘ 		SCIE ⓘ 26.0 HEMATOLOGY;IMMUNOLOGY;ONCOLOGY;TRANSPLANTATION
HEMATOLOGY;ONCOLOGY ⓘ 		zhaolei.zhang@utoronto.ca;hjoonk@chonnam.ac.kr;dr.dennis.kim@uhn.ca;
ihkimmd@snu.ac.kr;hjoonk@chonnam.ac.kr; ⓘ
Kim, Mihee
(Kim, M) ⓘ 		Chonnam Natl Univ, Hwasun Hosp, Dept Internal Med, Gwangju, South Korea ⓘ
ⓘ
ⓘ 		[JCR상위 26.0] Allogeneic transplant can abrogate the risk of relapse in the patients of first remission acute myeloid leukemia with detectable measurable residual disease by next-generation sequencing ⓘ SCIE ⓘ 26.0 HEMATOLOGY;IMMUNOLOGY;ONCOLOGY;TRANSPLANTATION ⓘ zhaolei.zhang@utoronto.ca;hjoonk@chonnam.ac.kr;dr.dennis.kim@uhn.ca; ⓘ
Kim, Seok Jin
(Kim, SJ) ⓘ 		Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Div Hematol Oncol,Dept Med, Seoul, South Korea ⓘ HII-5042-2022
Kim, Hee Young ⓘ
ⓘ 		[JCR상위 26.0] Open-label, single arm, multicenter phase II study of VIDL induction chemotherapy followed by upfront autologous stem cell transplantation in patients with advanced stage extranodal NK/T-cell lymphoma ⓘ SCIE ⓘ 26.0 HEMATOLOGY;IMMUNOLOGY;ONCOLOGY;TRANSPLANTATION ⓘ drydh1685@hotmail.com;wskimsmc@skku.edu; ⓘ
Kim, TaeHyung
(Kim, T) ⓘ 		Univ Toronto, Donnelly Ctr Cellular & Biomol Res, Toronto, ON, Canada
Univ Toronto, Dept Comp Sci, Toronto, ON, Canada ⓘ 		O-4252-2015
Kim, Tae ⓘ
ⓘ 		[JCR상위 26.0] Allogeneic transplant can abrogate the risk of relapse in the patients of first remission acute myeloid leukemia with detectable measurable residual disease by next-generation sequencing ⓘ SCIE ⓘ 26.0 HEMATOLOGY;IMMUNOLOGY;ONCOLOGY;TRANSPLANTATION ⓘ zhaolei.zhang@utoronto.ca;hjoonk@chonnam.ac.kr;dr.dennis.kim@uhn.ca; ⓘ
Kim, Won Seog
(Kim, WS) ⓘ 		교신저자 Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Div Hematol Oncol,Dept Med, Seoul, South Korea ⓘ C-9613-2011
Kim, Won ⓘ
ⓘ 		[JCR상위 26.0] Open-label, single arm, multicenter phase II study of VIDL induction chemotherapy followed by upfront autologous stem cell transplantation in patients with advanced stage extranodal NK/T-cell lymphoma ⓘ SCIE ⓘ 26.0 HEMATOLOGY;IMMUNOLOGY;ONCOLOGY;TRANSPLANTATION ⓘ drydh1685@hotmail.com;wskimsmc@skku.edu; ⓘ
Kurita, Takio
(Kurita, T) ⓘ 		Hiroshima Univ, Grad Sch Adv Sci & Engn, Higashihiroshima, Hiroshima 7398521, Japan ⓘ D-8674-2012
Kurita, Takio ⓘ 		0000-0003-3982-6750
Kurita, Takio ⓘ 		[JCR상위 26.0] Leveraging network using controlled weight learning approach for thyroid cancer lymph node detection ⓘ SCIE ⓘ 26.0 ENGINEERING, BIOMEDICAL ⓘ kavitha@nagasaki-u.ac.jp; ⓘ
Lee, Gyeong-Won
(Lee, GW) ⓘ 		Gyeongsang Natl Univ, Coll Med, Gyeongsang Natl Univ Hosp, Dept Internal Med, Jinju, South Korea ⓘ
ⓘ
ⓘ 		[JCR상위 26.0] Open-label, single arm, multicenter phase II study of VIDL induction chemotherapy followed by upfront autologous stem cell transplantation in patients with advanced stage extranodal NK/T-cell lymphoma ⓘ SCIE ⓘ 26.0 HEMATOLOGY;IMMUNOLOGY;ONCOLOGY;TRANSPLANTATION ⓘ drydh1685@hotmail.com;wskimsmc@skku.edu; ⓘ
Lee, Hui Young
(Lee, HY) ⓘ 		Kangwon Natl Univ, Kangwon Natl Univ Hosp, Sch Med, Dept Internal Med, Chunchon, South Korea
Univ Toronto, Dept Med Oncol & Hematol, Princess Margaret Canc Ctr, Toronto, ON, Canada ⓘ
ⓘ
ⓘ 		[JCR상위 26.0] Allogeneic transplant can abrogate the risk of relapse in the patients of first remission acute myeloid leukemia with detectable measurable residual disease by next-generation sequencing ⓘ SCIE ⓘ 26.0 HEMATOLOGY;IMMUNOLOGY;ONCOLOGY;TRANSPLANTATION ⓘ zhaolei.zhang@utoronto.ca;hjoonk@chonnam.ac.kr;dr.dennis.kim@uhn.ca; ⓘ
Lee, Ja-Yeon
(Lee, JY) ⓘ 		Chonnam Natl Univ, Hwasun Hosp, Genom Res Ctr Hematopoiet Dis, Jeollanam, South Korea ⓘ
ⓘ
ⓘ 		[JCR상위 26.0] Allogeneic transplant can abrogate the risk of relapse in the patients of first remission acute myeloid leukemia with detectable measurable residual disease by next-generation sequencing ⓘ SCIE ⓘ 26.0 HEMATOLOGY;IMMUNOLOGY;ONCOLOGY;TRANSPLANTATION ⓘ zhaolei.zhang@utoronto.ca;hjoonk@chonnam.ac.kr;dr.dennis.kim@uhn.ca; ⓘ
Novitzky-Basso, Igor
(Novitzky-Basso, I) ⓘ 		Univ Toronto, Dept Med Oncol & Hematol, Princess Margaret Canc Ctr, Toronto, ON, Canada ⓘ AAU-2356-2020
Novitzky-Basso, Igor ⓘ 		0000-0003-3748-3117
Novitzky-Basso, Igor ⓘ 		[JCR상위 26.0] Allogeneic transplant can abrogate the risk of relapse in the patients of first remission acute myeloid leukemia with detectable measurable residual disease by next-generation sequencing ⓘ SCIE ⓘ 26.0 HEMATOLOGY;IMMUNOLOGY;ONCOLOGY;TRANSPLANTATION ⓘ zhaolei.zhang@utoronto.ca;hjoonk@chonnam.ac.kr;dr.dennis.kim@uhn.ca; ⓘ
Park, Seong-Kyu
(Park, SK) ⓘ 		Soon Chun Hyang Univ Hosp, Dept Hematol Oncol, Bucheon, South Korea ⓘ
ⓘ
ⓘ 		[JCR상위 26.0] Allogeneic transplant can abrogate the risk of relapse in the patients of first remission acute myeloid leukemia with detectable measurable residual disease by next-generation sequencing ⓘ SCIE ⓘ 26.0 HEMATOLOGY;IMMUNOLOGY;ONCOLOGY;TRANSPLANTATION ⓘ zhaolei.zhang@utoronto.ca;hjoonk@chonnam.ac.kr;dr.dennis.kim@uhn.ca; ⓘ
페이지 이동: